Kohjin Bio Co Ltd (177A)

Currency in JPY
1,769.00
+4.00(+0.23%)
Closed·

177A Financial Summary

Key Ratios

P/E Ratio10.8
Price/Book1.5
Debt / Equity41.27%
Return on Equity17.41%
Dividend Yield1.36%
EBITDA1.35B
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2022
31/03
2023
31/03
2024
31/03
2025
31/03
* In Millions of JPY (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 157.41%
Dividend Yield
1.36%
Industry Median 2.49%
Annualised payout
24.00
Paid unevenly
5-Years Growth
-
Growth Streak

Earnings

Latest Release
May 14, 2025
EPS / Forecast
54.62 / --
Revenue / Forecast
1.28B / --
EPS Revisions
Last 90 days

FAQ

What were Kohjin Bio's earnings for the latest quarter?

The Kohjin Bio EPS (TTM) is 157.41. Kohjin Bio reported sales of 1,283.00, net income of 278.00, and EPS of 54.62 for the latest quarter.

What was Kohjin Bio's net income for the latest quarter?

Kohjin Bio's net income for the latest quarter was 278.00.

How did Kohjin Bio's performance compare year-over-year in the latest quarter?

The company's revenue moved from 1,416.00 in the previous quarter to 1,283.00 in the latest quarter, and net income moved from 239.00 to 278.00 compared to the previous quarter.

What is Kohjin Bio's net profit margin on a TTM basis?

Kohjin Bio's trailing twelve months (TTM) net profit margin is 15.25%.

How does Kohjin Bio's debt to equity ratio compare to industry standards?

Kohjin Bio's total debt-to-equity ratio is 41.27%.

What is Kohjin Bio's return on investment on a TTM basis?

Kohjin Bio's trailing twelve months (TTM) return on investment (ROI) is 17.41%.

What were Kohjin Bio's total assets and liabilities in the latest quarter?

As of the latest quarter, Kohjin Bio reported total assets of 9,066.00 million and total liabilities of 2,487.00 million.

How has Kohjin Bio's total revenue grown this year?

Kohjin Bio's total revenue was 1,416.00 in the previous quarter and 1,283.00 in the latest quarter.

What is Kohjin Bio's gross margin on a TTM basis?

Kohjin Bio's trailing twelve months (TTM) gross margin is 45.43%.

What was Kohjin Bio's revenue per share for the latest quarter?

Kohjin Bio's revenue per share for the latest quarter was 1,857.39.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.